Evidence map›Paper›PMID 27815572›Full record

Trial reportCancer immunology, immunotherapy : CII2017

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Maria Winqvist, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson, Håkan Mellstedt, Anders Österborg, Jeanette Lundin

Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer immunology, immunotherapy : CII, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maria WinqvistDepartment of Hematology, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden. maria.winqvist@karolinska.se.
Fariba MozaffariDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Marzia PalmaDepartment of Hematology, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden.
Sandra Eketorp SylvanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Lotta HanssonDepartment of Hematology, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden.
Håkan MellstedtDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Anders ÖsterborgDepartment of Hematology, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden.
Jeanette LundinDepartment of Hematology, Karolinska University Hospital Solna, 171 76, Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This phase I-II study explored safety, immunomodulatory and clinical effects of lenalidomide (weeks 1-16) and alemtuzumab (weeks 5-16) in 23 patients with refractory chronic lymphocytic leukemia. Most patients had Rai stage III/IV disease and were heavily pretreated (median 4 prior therapies), and 61% had del(17p)/del(11q). Eleven of 19 evaluable patients (58%) responded, with a median response duration of 12 months (1-29+); time to progression was short in non-responders. Lenalidomide had a narrow therapeutic dose range, 2.5 mg/day was not efficient, and maximum tolerated dose was 5 mg/day. Grade 3-4 neutropenia and thrombocytopenia occurred in 84 and 55%, 30% had febrile neutropenia, and CMV-reactivation requiring valganciclovir occurred in 30% of patients. The frequency of proliferating (Ki67

Indexed as

AgedAged, 80 and overAlemtuzumabAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleHLA-DR AntigensHumansKiller Cells, NaturalLenalidomideLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedAlemtuzumabAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanHLA-DR AntigensLenalidomidePDCD1 protein, humanProgrammed Cell Death 1 ReceptorThalidomideAlemtuzumabChronic lymphocytic leukemiaImmune checkpointsLenalidomideT cells

Identifiers

PMID27815572
PMCPMC5222940
OpenAlexW2546805667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.